Inovio Pharmaceuticals, Inc. News (NASDAQ:INO)

DateTimeSource
Headline
01/17/20188:00AMGLOBEInovio’s Co-Founder along with its Lead Antigen Designer Named Among Top 20 Researchers With Most Granted U.S Patents for ...
PLYMOUTH MEETING, Pa., Jan. 17, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. David B. Weiner, its co-founder; and Dr. Jian Yan, the company’s Lead Antigen Designer, have been selected as two of the “Top 20 Translational Researchers” for the year 2016 by the editors of... More...>>
01/09/20188:00AMGLOBEInovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy Establish Clinical Development Collaboration To Eval...
Advances development of Inovio’s ASPIRE™ (Antigen SPecific Immune REsponses) immunotherapy platform as a foundation for novel combination regimen approachesEngages the Parker Institute’s extensive immunotherapy expertise and academic and research network on studies that have the potential to address cancers with... More...>>
01/08/20188:00AMGLOBEInovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squa...
PLYMOUTH MEETING, Pa., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today it has received a milestone payment from MedImmune as MEDI0457 (formerly called INO-3112 which MedImmune in-licensed from Inovio) in combination with durvalumab (MEDI4736) satisfactorily completed the phase... More...>>
01/02/20188:00AMGLOBEInovio Enters License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China
PLYMOUTH MEETING, Pa., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it entered an amended agreement providing ApolloBio Corporation (NEEQ:430187) with the exclusive right to develop and commercialize VGX-3100, Inovio’s DNA immunotherapy product designed to treat pre-cancers... More...>>
12/11/20178:00AMGLOBEInovio Pharmaceuticals Promotes Dr. Laurent Humeau to Senior Vice President, Research & Development
PLYMOUTH MEETING, Pa., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has promoted Dr. Laurent Humeau to Senior Vice President, Research & Development, reporting to Dr. J. Joseph Kim, Inovio’s President & CEO. Dr. Humeau joined Inovio in 2014 as Vice President, R&D. Dr. Humeau... More...>>
12/06/20178:00AMGLOBEInovio Pharmaceuticals Appoints Wendy Yarno To its Board of Directors
PLYMOUTH MEETING, Pa., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Wendy Yarno has been elected to the company's Board of Directors. Wendy Yarno has over 25 years of experience in the pharmaceutical industry highlighted by her tenure at Merck & Co. where she served... More...>>
11/29/20178:00AMGLOBEInovio’s Further Analysis of VGX-3100 Phase 2b Data Reveals Immune Correlates and Biomarker Signatures That Predicted Clini...
PLYMOUTH MEETING, Pa., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that post-hoc analysis of data generated from its phase 2b trial of VGX-3100 identified immune correlates and biomarker signatures predictive of treatment success.  VGX-3100, Inovio’s lead product now in... More...>>
11/27/20178:00AMGLOBEInovio Pharmaceuticals SynCon® TERT Cancer Immunotherapy Combined with Checkpoint Inhibitor Synergistically Shrinks Tumor a...
PLYMOUTH MEETING, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) demonstrated the synergistic effect of combining Inovio’s TERT (telomerase reverse transcriptase) cancer immunotherapy in combination with a checkpoint inhibitor in preclinical tumor model. The combination therapies resulted... More...>>
11/10/201710:27AMGLOBEInovio Pharmaceuticals Presents Immuno-Oncology Advancements At Society for Immunotherapy of Cancer Conference
PLYMOUTH MEETING, Pa., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that two of its cancer immunotherapies demonstrated antigen-specific T-cell stimulation in phase 1 studies. INO-3112 (now called MEDI0457), an investigational T-cell activation immunotherapy that targets cancers... More...>>
11/09/20178:00AMGLOBEInovio Pharmaceuticals to Participate In Upcoming Investment Conferences
PLYMOUTH MEETING, Pa., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will participate in the following upcoming investment conferences: Stifel 2017 Healthcare ConferencePresentation and 1x1 meetingsDr. Niranjan Y. Sardesai, COO11:45 AM ET, November 15, 2017New... More...>>
11/08/20174:05PMGLOBEInovio Pharmaceuticals Reports 2017 Third Quarter Financial Results
PLYMOUTH MEETING, Pa., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the quarter ended September 30, 2017. Total revenue was $2.6 million for the three months ended September 30, 2017, compared to $12.5 million for the same period in 2016. Total operating... More...>>
11/01/20179:18AMGLOBEInovio Pharmaceuticals Initiates Immuno-Oncology Clinical Study for Glioblastoma in Combination with Regeneron’s PD-1 Inhi...
PLYMOUTH MEETING, Pa., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today initiated a phase 1b/2a immuno-oncology trial in patients with newly diagnosed glioblastoma (GBM) designed to evaluate cemiplimab (also known as REGN2810), a PD-1 inhibitor developed by Regeneron Pharmaceuticals, Inc... More...>>
10/26/20178:00AMGLOBEInovio Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 8, 2017
PLYMOUTH MEETING, Pa., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2017 third quarter financial results on Wednesday, November 8, 2017 at 4:30 p.m. ET. A live and archived version of the audio presentation... More...>>
10/24/20178:00AMGLOBEInovio and U.S. Army Co-developing Novel Vaccine That Completely Prevents Lethal Lassa Fever Infection in Pre-Clinical Study...
PLYMOUTH MEETING, Pa., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced results of a study in which a DNA vaccine provided 100% protection for non-human primates challenged with a lethal dose of the Lassa fever virus. Lassa is a virulent hemorrhagic virus, similar to Ebola, which... More...>>
10/16/20177:00AMGLOBEInovio Pharmaceuticals Begins Phase 1b/2 Cancer Efficacy Trial Combining Its T-cell Immunotherapy with a PD-L1 Checkpoint Inh...
PLYMOUTH MEETING, Pa., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced initiation of a phase 1b/2 immuno-oncology trial to evaluate Genentech/Roche’s atezolizumab (TECENTRIQ®) in combination with Inovio’s INO-5401, a T cell activating immunotherapy encoding multiple antigens... More...>>
10/05/20177:00AMGLOBEInovio’s Positive Zika Vaccine Clinical Study Data Published in New England Journal of Medicine
PLYMOUTH MEETING, Pa., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO)  reported today on positive safety and immune response results from a first-in-man, multi-center phase 1 trial of a vaccine against the Zika virus. The phase 1 trial of Inovio’s DNA-based Zika vaccine (GLS-5700) induced... More...>>
09/21/20178:00AMGLOBEInovio dMAb™ Constructs Shrink Prostate Tumors and Protect Against Lethal Antibiotic-Resistant Bacterial Infection In Prec...
PLYMOUTH MEETING, Pa., Sept. 21, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the development of its DNA-based monoclonal antibody program received a boost from two peer-reviewed scientific papers that demonstrate their impact on prostate tumors and in preventing infection from... More...>>
09/18/20178:00AMGLOBEInovio and Partners Initiate Phase 1/2a Clinical Trial To Further Advance Its Vaccine Against Deadly MERS Infection
PLYMOUTH MEETING, Pa., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Korean Ministry of Food and Drug Safety approved the initiation of a study to evaluate GLS-5300, Inovio’s vaccine against the MERS virus (Middle East Respiratory Syndrome), in a phase 1/2a trial... More...>>
09/11/20178:00AMGLOBEInovio’s Cancer Immunotherapy (INO-5150) Slowed PSA Rise and Significantly Increased PSA Doubling Times In Patients with R...
PLYMOUTH MEETING, Pa., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO), today announced that an interim data analysis showed that its INO-5150 cancer immunotherapy product generated antigen-specific CD8+ killer T cell responses measured in peripheral blood from subjects with biochemically recurrent... More...>>
08/23/20178:00AMGLOBEInovio Pharmaceuticals to Participate in Upcoming Investment Conferences
PLYMOUTH MEETING, Pa., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will participate in the following upcoming investment conferences: Citi’s 12th Annual Biotech ConferencePanel Discussion: I/O Beyond PD-1: Opportunities & ChallengesDr. J. Joseph Kim... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V:us D:20180120 05:00:01